In non-APL types of AML, a lack of therapeutic effect of ATRA is generally thought to be the lack of PML-RARA mutation, although, in principle, terminal differentiation programs may still be activated by ATRA via the intrinsic retinoid signaling pathway. The gene discussed is PML; the disease is acute promyelocytic leukemia.